Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, dismantling a factory that made jabs labelled as containing the ingredient in ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could ...

Analysts believe while the deal is positive, Cipla share price is unlikely to see fresh run up given the rise in the ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...